The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment. - Wikidata - awgldk - TriplyDB

The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment.

The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment.

http://www.wikidata.org/entity/Q35588860

about

Protein phosphatase 2A dysfunction in Alzheimer's disease Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease.Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease Protein phosphatases and Alzheimer's disease Memantine Attenuates Alzheimer's Disease-Like Pathology and Cognitive Impairment Silencing PP2A inhibitor by lenti-shRNA interference ameliorates neuropathologies and memory deficits in tg2576 mice.Silencing [Formula: see text] Rescues Tau Pathologies and Memory Deficits through Rescuing PP2A and Inhibiting GSK-3β Signaling in Human Tau Transgenic Mice.Cytoplasmic SET induces tau hyperphosphorylation through a decrease of methylated phosphatase 2A.Cytoplasmic retention of protein phosphatase 2A inhibitor 2 (I2PP2A) induces Alzheimer-like abnormal hyperphosphorylation of Tau.CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease.Asparagine endopeptidase is an innovative therapeutic target for neurodegenerative diseases.The N-terminal Set-β Protein Isoform Induces Neuronal Death APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in Alzheimer's disease transgenics Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease.Asperterpenes A and B, two unprecedented meroterpenoids from Aspergillus terreus with BACE1 inhibitory activities.Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease.Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles Further understanding of tau phosphorylation: implications for therapy.Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity.Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.Upregulation of SET expression by BACE1 and its implications in Down syndrome.Correcting the expression of miRNA-155 represses PP2Ac and enhances the release of IL-2 in PBMCs of juvenile SLE patients.An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide.Alzheimer disease and amyotrophic lateral sclerosis: an etiopathogenic connection Hyperphosphorylation-induced tau oligomers Sex Differences in the Cognitive and Hippocampal Effects of Streptozotocin in an Animal Model of Sporadic AD.Eicosanoyl-5-hydroxytryptamide (EHT) prevents Alzheimer's disease-related cognitive and electrophysiological impairments in mice exposed to elevated concentrations of oligomeric beta-amyloid.Upregulation of astrocytes protein phosphatase-2A stimulates astrocytes migration via inhibiting p38 MAPK in tg2576 mice.Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.Combination of PPT with LiCl Treatment Prevented Bilateral Ovariectomy-Induced Hippocampal-Dependent Cognition Deficit in Rats.Regulation of SET Gene Expression by NFkB.Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy.Trillium tschonoskii maxim extract attenuates abnormal Tau phosphorylation.Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration

P2860

Q21090465-3C9639EC-909C-4850-80A5-09D46074EBF9 Q24318458-238F8CBB-0953-468A-B4C6-C1A35E01A5B2 Q24563378-6687E6D1-2586-48A2-92B6-78E514E269EC Q24627125-19D1CD7F-86CF-4CF5-A78E-16CBC5DD026D Q24632495-E9ADCA9C-A512-4BF1-8657-32070352A6EE Q28551718-6A4F1637-CBDF-4102-9C8E-97345BE15779 Q30559506-2E205809-7C4B-46EC-A738-16880348CA81 Q33766526-0D4F0290-B250-4767-9F5B-BB0C66B8C9EF Q33861397-C0BA5670-1F34-485C-934C-3FF0B9F5E221 Q34283467-8F044F48-5DFD-42BF-AC06-F09193214219 Q34450215-17582B5A-8C4C-4894-9FC5-56D783CACFF5 Q34523642-8CDFB2F3-D54B-4111-8BB2-5D9703AD4CCA Q35861000-9188F537-140C-4671-8C5E-C04AE0F67523 Q35997607-D5F8C94D-27AB-4CDD-9912-A723A8DBF238 Q36929023-5487B65B-110E-44BA-A973-6BA2457FB6E2 Q37460357-47005E88-D830-4626-BB02-2979721D7EEC Q38126701-2F4853A5-EDE5-4679-AA04-D5A75E18C1CB Q38175453-2DE16830-F6DB-4C70-B0A2-C571CC89A143 Q38177975-4CC81C06-1684-4706-B202-EC3DAE4DA0AE Q38306065-6B78E51D-E20F-4EE2-B4C1-6719DCF54652 Q38592451-CEA43E92-3B98-49D1-A361-28C756665B33 Q38715233-99295513-F1DA-40A7-A980-3CD2A0B269FF Q38984026-42E29D6A-6DF7-48FE-A136-0925B39EC120 Q40189561-8B6D0878-CE75-41F0-9002-0DEC9D26AEB9 Q41866952-9A88C53F-E4BA-4F9A-A26B-28596A7E356B Q42003588-67BAD9CE-8A6C-4A4A-BA0C-F76040EAFB14 Q42555418-BFC8EF45-296C-4174-8908-4906287F5BA1 Q47107171-F3212E80-A0DD-4122-B4C9-C6EBB6233D0C Q47279111-F801074F-7DDD-4BE4-BFEC-E367FBAB210F Q47581778-CBEA9E5A-4F2B-42DC-B1F9-4AD73BE2BDFA Q48105635-B19186DC-14FB-4F75-BE3A-F32D712D65BE Q48402165-9632252F-56E1-4F51-B433-8E4CB905825F Q50502104-EF3F0C25-3D0E-4B68-A030-57E2E5169162 Q50632272-0AC4F902-647B-41E0-9DA6-EA15F09F8B05 Q55404325-1F3F8B04-2DD7-4C5A-805C-C703F5616E06 Q58769184-DA9E0512-BB2E-4719-A7D6-51DDEF69901C

P2860

The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment.

http://www.wikidata.org/entity/Q35588860

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

The carboxy-terminal fragment ...... logy and cognitive impairment.

@ast

The carboxy-terminal fragment ...... logy and cognitive impairment.

@en

type

label

The carboxy-terminal fragment ...... logy and cognitive impairment.

@ast

The carboxy-terminal fragment ...... logy and cognitive impairment.

@en

prefLabel

The carboxy-terminal fragment ...... logy and cognitive impairment.

@ast

The carboxy-terminal fragment ...... logy and cognitive impairment.

@en

P1433

Q35588860-2476C441-0D45-4913-B37C-EEC8536C31C7

P1476

Q35588860-3FD37824-7DBD-4122-862C-90833D162851

P2093

Q35588860-030EA9B4-CF36-46F9-8284-8508E9C75FD5

Q35588860-5645BB82-30AB-40C5-97E2-DFA916788482

Q35588860-79957986-7682-43B6-9EB8-FA420C427AD6

Q35588860-BE7EA297-E7F5-460F-A958-09EE47412BE2

Q35588860-C4E4C3F3-E73E-419C-AFE0-2863842F9391

Q35588860-D770DB9C-E3EC-4802-BEFD-DA5D7F80869F

Q35588860-EAEC0005-AAAE-44BA-8691-2363AF154674

P2860

Q35588860-007E7E38-C65F-4ACC-BA23-DFF1EF0544BF

Q35588860-00A553D7-E30B-4EC0-B540-7CFB1E2187E4

Q35588860-02D5F317-8390-4DB2-BB43-AD8FDCA71342

Q35588860-071631B6-EABC-4F86-B061-FC3197A2712C

Q35588860-0F4C365B-D674-41DA-A755-50E6060CC55D

Q35588860-1243EFC5-1A35-4296-BE1D-0CDE02E4085E

Q35588860-1B124D33-328A-4586-ACDB-226E167401C2

Q35588860-1C0D1C35-D3B1-4554-ABB8-B4F3DA828C65

Q35588860-24B30FE3-4245-4E08-9D1A-8FCB75A63E63

Q35588860-295D1439-9BF9-48DE-817F-F116CFA985B8

P304

Q35588860-3C481453-CD0D-4E9B-AB77-B13226307CF7

P31

Q35588860-13E9C5DC-837A-4750-A9E7-D76743A47337

P356

Q35588860-1BF0D694-C521-4171-A83C-1DC0E21612FE

P407

Q35588860-54FD201A-52FF-43D6-AB96-22F8F04871BF

P433

Q35588860-3F20382B-16B1-4553-A5F5-C2A2FFFADAAC

P478

Q35588860-BD1A013F-D9D2-4066-8EA5-0A9E3D3F49F9

P50

Q35588860-A960454D-17E8-467D-83D0-24B84C2AA121

P577

Q35588860-7A2B0BDF-112A-4CFA-BECF-D81BEFDFF2A0

P698

Q35588860-A77643B2-2509-4308-8770-2B68D266CB7D

P921

Q35588860-7B8AF2D6-F55E-4538-B2FB-58E30F874BA4

P932

Q35588860-36C30A1E-A46B-401C-A2F7-637A1735C62B

P356

P1433

P1476

The carboxy-terminal fragment ...... logy and cognitive impairment.

@en

P2093

Aurelian Radu

http://www.w3.org/2001/XMLSchema#string

Erik Kohlbrenner

http://www.w3.org/2001/XMLSchema#string

Julie Blanchard

http://www.w3.org/2001/XMLSchema#string

Khalid Iqbal

http://www.w3.org/2001/XMLSchema#string

Nathalie Clement

http://www.w3.org/2001/XMLSchema#string

R Michael Linden

http://www.w3.org/2001/XMLSchema#string

Xiaochuan Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Neuroprotective actions of PIKE-L by inhibition of SET proteolytic degradation by asparagine endopeptidase

Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

Characterization of tau phosphorylation in glycogen synthase kinase-3beta and cyclin dependent kinase-5 activator (p23) transfected cells

Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17

I1PP2A affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

The distribution of tau in the mammalian central nervous system

Site-specific integration of adeno-associated virus involves partial duplication of the target locus.

Inhibition of PP-2A upregulates CaMKII in rat forebrain and induces hyperphosphorylation of tau at Ser 262/356.

P304

4420-4432

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1096/FJ.10-158477

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Inge Grundke-Iqbal

P577

2010-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20651003

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3229424

http://www.w3.org/2001/XMLSchema#string